Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model

Brain

Volumn 137, Issue 2, 2014, Pages 380-401

  Guidi, Sandra ^a   Stagni, Fiorenza ^a   Bianchi, Patrizia ^a   Ciani, Elisabetta ^a   Giacomini, Andrea ^a   De Franceschi, Marianna ^a   Moldrich, Randal ^b   Kurniawan, Nyoman ^b   Mardon, Karine ^b   Giuliani, Alessandro ^c   Calzà, Laura ^c   Bartesaghi, Renata ^a  

^a Department of Biomedical and Neuromotor Sciences Physiology Building ^*  (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

brain development; Down's syndrome; intellectual disability; neurogenesis impairment; preventive pharmacotherapy

Indexed keywords

BROXURIDINE; FLUOXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; BRAIN DEVELOPMENT; BRAIN SIZE; BRAIN WEIGHT; CELL PROLIFERATION; CELL SURVIVAL; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; CORTICAL THICKNESS (BRAIN); DELIVERY; DENTATE GYRUS; DOWN SYNDROME; EMBRYO; EMBRYO DEVELOPMENT; FETAL WELL BEING; FOREBRAIN; GENOTYPE; GRANULE CELL; HIPPOCAMPUS; HYPOTHALAMUS; INTELLECTUAL IMPAIRMENT; MESENCEPHALON; MOUSE; NEOCORTEX; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINATAL PERIOD; PHENOTYPE; PONS; PRENATAL CARE; PRIORITY JOURNAL; RHOMBENCEPHALON; SUBGRANULAR ZONE; SUBVENTRICULAR ZONE; SURVIVAL RATE; SYNAPSE; THALAMUS; TREATMENT DURATION;

BRAIN DEVELOPMENT; DOWN'S SYNDROME; INTELLECTUAL DISABILITY; NEUROGENESIS IMPAIRMENT; PREVENTIVE PHARMACOTHERAPY;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; FLUOXETINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROGENESIS; PREGNANCY; PRENATAL CARE;

EID: 84893844155     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt340     Document Type: Article

References (69)

1. Adriani W, Koot S, Columba-Cabezas S, Romano E, Travaglini D, van Den Bos R, et al. Immunization with DAT fragments is associated with long-Term striatal impairment, hyperactivity and reduced cognitive flexibility in mice. Behav Brain Funct 2012; 8: 54
2. Altafaj X, Martin ED, Ortiz-Abalia J, Valderrama A, Lao-Peregrin C, Dierssen M, et al. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 2013; 52: 117-27
3. Altman J, Bayer S. Postnatal development of the hippocampal dentate gyrus under normal and experimental conditions. In: Isaacson RL, Pribram KH, editors. The hippocampus. Vol. 1. New York and London: Plenum Press; 1975. p. 95-122
4. Angevine JB Jr. Time of neuron origin in the hippocampal region. An autoradiographic study in the mouse. Exp Neurol 1965; 2: 1-70
5. Angevine JBJ. Development of the hippocampal region. In: Isaacson RL, Pribram KH, editors. The hippocampus. Vol. 1. New York and London: Plenum Press; 1975. p. 61-91
6. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004; 29: 450-60
7. Bar-Peled O, Gross-Isseroff R, Ben-Hur H, Hoskins I, Groner Y, Biegon A. Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neurosci Lett 1991; 127: 173-6
8. Bartesaghi R, Guidi S, Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Rev Neurosci 2011; 22: 419-55
9. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 2000; 9: 195-202
10. Bayer SA, Wills KV, Triarhou LC, Ghetti B. Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res 1995; 105: 191-9
11. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol 2004; 480: 281-98
12. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G, et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30: 8769-79
13. Blazek JD, Billingsley CN, Newbauer A, Roper RJ. Embryonic and not maternal trisomy causes developmental attenuation in the Ts65Dn mouse model for Down syndrome. Dev Dyn 2010; 239: 1645-53
14. Bouet V, Klomp A, Freret T, Wylezinska-Arridge M, Lopez-Tremoleda J, Dauphin F, et al. Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology (Berl) 2012; 221: 329-39
15. Boylan K, Romero S, Birmaher B. Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology (Berl) 2007; 191: 27-38
16. Brazel CY, Romanko MJ, Rothstein RP, Levison SW. Roles of the mammalian subventricular zone in brain development. Prog Neurobiol 2003; 69: 49-69
17. Carmona S, Proal E, Hoekzema EA, Gispert JD, Picado M, Moreno I, et al. Ventro-striatal reductions underpin symptoms of hyperactivity and impulsivity in attention-deficit/hyperactivity disorder. Biol Psychiatry 2009; 66: 972-7
18. Chakrabarti L, Galdzicki Z, Haydar TF. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci 2007; 27: 11483-95
19. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-87
20. Chan WY, Lorke DE, Tiu SC, Yew DT. Proliferation and apoptosis in the developing human neocortex. Anat Rec 2002; 267: 261-76
21. Clark S, Schwalbe J, Stasko MR, Yarowsky PJ, Costa AC. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 2006; 200: 256-61
22. Contestabile A, Fila T, Bartesaghi R, Ciani E. Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain Pathol 2009; 19: 224-37
23. Contestabile A, Fila T, Ceccarelli C, Bonasoni P, Bonapace L, Santini D, et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007; 17: 665-78
24. Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N, et al. Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci 2005; 21: 1-14
25. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can J Psychiatry 2009; 54: 242-6
26. Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 2006; 103: 8233-8
27. Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G. Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kappaB in brains of patients with Down syndrome. J Neural Transm Suppl 2001; 61: 181-92
28. Faber KM, Haring JH. Synaptogenesis in the postnatal rat fascia dentata is influenced by 5-HT1a receptor activation. Brain Res Dev Brain Res 1999; 114: 245-52
29. Fentress JC, Stanfield BB, Cowan WM. Observation on the development of the striatum in mice and rats. Anat Embryol (Berl) 1981; 163: 275-98
30. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 1997
31. Guedj F, Bianchi DW. Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome. Prenat Diagn 2013; 33: 614-8
32. Guidi S, Bonasoni P, Ceccarelli C, Santini D, Gualtieri F, Ciani E, et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 2008; 18: 180-97
33. Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R. Widespread Proliferation Impairment and Hypocellularity in the Cerebellum of Fetuses with Down Syndrome. Brain Pathol 2011; 21: 361-73
34. Guidi S, Stagni F, Bianchi P, Ciani E, Ragazzi E, Trazzi S, et al. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of Down syndrome. Brain Pathol 2013; 23: 129-43
35. Haydar TF, Nowakowski RS, Yarowsky PJ, Krueger BK. Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. J Neurosci 2000; 20: 4156-64
36. Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD, Mitchel E, et al. Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies. Am J Obstet Gynecol 2012; 207: 49 e1-9
37. Heinen M, Hettich MM, Ryan DP, Schnell S, Paesler K, Ehninger D. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast 2012; 2012: 467251
38. Incerti M, Horowitz K, Roberson R, Abebe D, Toso L, Caballero M, et al. Prenatal treatment prevents learning deficit in Down syndrome model. PLoS One 2012; 7: E50724
39. Ishii Y, Bouret SG. Embryonic birthdate of hypothalamic leptin-Activated neurons in mice. Endocrinology 2012; 153: 3657-67
40. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 2012; 32: 9217-27
41. Liu C, Belichenko PV, Zhang L, Fu D, Kleschevnikov AM, Baldini A, et al. Mouse models for Down syndrome-Associated developmental cognitive disabilities. Dev Neurosci 2011; 33: 404-13
42. Lorenzi HA, Reeves RH. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 2006; 1104: 153-9
43. Lu J, Esposito G, Scuderi C, Steardo L, Delli-Bovi LC, Hecht JL, et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS One 2012; 6: E22126
44. Malberg JE, Blendy JA. Antidepressant action: To the nucleus and beyond. Trends Pharmacol Sci 2005; 26: 631-8
45. McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, et al. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science 2007; 317: 94-9
46. Mogha A, Guariglia SR, Debata PR, Wen GY, Banerjee P. Serotonin 1A receptor-mediated signaling through ERK and PKCalpha is essential for normal synaptogenesis in neonatal mouse hippocampus. Transl Psychiatry 2012; 2: E66
47. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA 2005; 293: 2372-83
48. Olivier J, Akerud H, Kaihola L, Pawluski J, Skalkidou S, Hogberg U, et al. The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. 2013; 7: 73
49. Park J, Oh Y, Yoo L, Jung MS, Song WJ, Lee SH, et al. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J Biol Chem 2010; 285: 31895-906
50. Paxinos G, Halliday G, Watson C, Koutcherov Y, Wang H. Atlas of the developing mouse brain. Amsterdam: Academic Press; 2007
51. Pechnick RN, Zonis S, Wawrowsky K, Cosgayon R, Farrokhi C, Lacayo L, et al. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One 2011; 6: E27290
52. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010; 125: E600-8
53. Rachidi M, Lopes C. Mental retardation and associated neurological dysfunctions in Down syndrome: A consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 2008; 12: 168-82
54. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 1995; 11: 177-84
55. Reinholdt LG, Ding Y, Gilbert GJ, Czechanski A, Solzak JP, Roper RJ, et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome 2011; 22: 685-91
56. Risser D, Lubec G, Cairns N, Herrera-Marschitz M. Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 1997; 60: 1231-7
57. Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH. Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc Natl Acad Sci USA 2006; 103: 1452-6
58. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9
59. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet 2005; 365: 482-7
60. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000; 182: 311-22
61. Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, et al. Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 2006; 98: 1266-77
62. Sillitoe RV, Joyner AL. Morphology, molecular codes, and circuitry produce the three-dimensional complexity of the cerebellum. Annu Rev Cell Dev Biol 2007; 23: 549-77
63. Sudarov A, Joyner AL. Cerebellum morphogenesis: The foliation pattern is orchestrated by multi-cellular anchoring centers. Neural Dev 2007; 2: 26
64. Suzuki-Hirano A, Ogawa M, Kataoka A, Yoshida AC, Itoh D, Ueno M, et al. Dynamic spatiotemporal gene expression in embryonic mouse thalamus. J Comp Neurol 2011; 519: 528-43
65. Takahashi T, Nowakowski RS, Caviness VS Jr. The leaving or Q fraction of the murine cerebral proliferative epithelium: A general model of neocortical neuronogenesis. J Neurosci 1996; 16: 6183-96
66. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008; 28: 1374-84
67. Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 2008; 15: 1176-83
68. West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990; 296: 1-22
69. Whitaker-Azmitia PM. Serotonin and brain development: Role in human developmental diseases. Brain Res Bull 2001; 56: 479-85